Bradley Mills, Ph.D., and Scott Gerber, Ph.D., in the Gerber Lab
Wilmot Cancer Institute research team reports that combining a type of radiation therapy with immunotherapy not only cures pancreatic cancer in mice, but appears to reprogram the immune system to create an “immune memory” in the same way that a vaccine keeps the flu away.
The result is that the combination treatment also destroyed pancreatic cells that had spread to the liver, a common site for metastatic disease.
The journal Cell Reports published the study, with Scott Gerber, Ph.D., as corresponding author, and Bradley Mills, Ph.D., a post-doctoral fellow in the Gerber Lab, as first author. They led a large team of collaborators from the University of Rochester departments of Surgery, Microbiology and Immunology, Pathology and Laboratory Medicine, Radiation Oncology, and Environmental Medicine.
Pancreatic cancer is aggressive and generally has poor survival odds. It’s been in the news this year after “Jeopardy!” host Alex Trebek went public with his diagnosis and treatment. In more than 80 percent of patients, the cancer is discovered in later stages when surgery is not an option and chemotherapy is usually not effective beyond stabilizing the disease.
Pancreatic tumors are notoriously hard to treat because they are surrounded by a toxic stew of proteins and other tissues that protect the cancer cells from the immune system’s natural role to attack invaders.
Wilmot researchers looked for an innovative treatment combination that could do two things at once: activate T-cells to attack the cancer and convert the immune-suppressing cells into fighters, the study said.
The combination they used in laboratory models consisted of stereotactic body radiotherapy (SBRT), which delivers high doses of radiation over a short period of time and may also prime the immune system to kill cancer cells; and interleukin-12 (IL-12), which has well-known anti-cancer activity and also activates the immune system. However, IL-12 often comes with harsh side effects. To solve that problem, researchers are testing a timed-release technology in a specially designed mouse model for pancreatic cancer, which would slowly deliver the drug over two weeks.
The preclinical laboratory investigation resulted in Gerber’s team receiving a $2 million National Cancer Institute grant in July to continue the research, which includes moving the findings into clinical trials in the future. Gerber is an assistant professor and co-director of the Center for Tumor Immunology Research.
Learn more: Study: Innovative Pancreatic Cancer Treatment May Rev Up Immune System
The Latest on: Pancreatic cancer treatment
via Google News
The Latest on: Pancreatic cancer treatment
- Tom Watson's wife, Hilary Watson, dies of pancreatic canceron November 29, 2019 at 11:03 am
Hilary Watson, wife of eight-time major champion Tom Watson, died on Wednesday after a two-year battle with pancreatic cancer ... According to John Feinstein of Golf Digest, the cancer returned just a ...
- Branched-chain amino acids sustain pancreatic cancer growth by regulating lipid metabolismon November 29, 2019 at 2:45 am
neither the level of tricarboxylic acid (TCA) cycle intermediates nor the oxygen consumption rate was altered upon BCKDHA knockdown; however, BCKDHA knockdown led to a dramatic reduction in the levels ...
- Non-SMC condensin I complex subunit H mediates mature chromosome condensation and DNA damage in pancreatic cancer cellson November 29, 2019 at 2:20 am
However, the mechanisms through which NCAPH affects pancreatic cancer (PC) and its molecular function remain unclear ... Cells were treated with colcemid (0.1 µg/mL) for 4 h and then harvested. After ...
- Golfer Tom Watson's Wife Hilary Dies at 63 from Pancreatic Canceron November 28, 2019 at 12:57 pm
Hilary Watson, the wife of golfer Tom Watson, has died from pancreatic cancer at the age of 63 ... Hilary remained active throughout her treatment for cancer. She competed in horse-cutting ...
- Advances in Health: New Hope for Pancreatic Cancer Patientson November 28, 2019 at 5:00 am
In fact, about 95% of all pancreatic cancers are within the exocrine system. The report most common form of pancreatic cancer is adenocarcinoma, an exocrine cancer. What are Treatments for Pancreatic ...
- "Extraordinary responders" could hold clues to helping others with pancreatic canceron November 26, 2019 at 8:44 pm
host Alex Trebek are two well-known patients who have fought it. But a group of patients, who are not celebrities, could help change the future of treatment for others. Three years ago, Arnold Simon's ...
- "Extraordinary responders" could hold clues to pancreatic cancer treatmenton November 26, 2019 at 4:29 pm
A group of patients known as "extraordinary responders" have had a dramatic response to treatment for pancreatic cancer. They could help researchers determine how to help others. Dr. Jon LaPook ...
- Newly developed personalized vaccine system could delay onset of pancreatic canceron November 26, 2019 at 10:44 am
By injecting these virus-infected cells into mice that were destined to develop pancreatic cancer, the team were able to delay the onset of disease, doubling their survival time when compared with ...
- Researchers take first steps toward a vaccine for pancreatic canceron November 26, 2019 at 6:10 am
That means treatments that are effective for one patient's cancer may not be effective ... at-risk individuals and used to create matching tumor cells for use in a vaccine regime tailored to those ...
- Theranostic Approach for Pancreatic Cancer, 2019 - ResearchAndMarkets.comon November 25, 2019 at 7:04 am
Additionally, it encompasses a discussion on theranostic clinical applications for personalized treatment and management of pancreatic cancer. The book is a valuable resource for cancer researchers, ...
via Bing News